J Cancer 2018; 9(7):1277-1286. doi:10.7150/jca.22005 This issue


Wnt signaling in cervical cancer?

Min Yang1, Min Wang1✉, Xianping Li1, Yixin Xie1, Xiaomeng Xia2, Jingjing Tian1, Kan Zhang1, Aiguo Tang1

1. Department of Laboratory Medicine, the Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China;
2. Department of Obstetrics and Gynecology, the Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Yang M, Wang M, Li X, Xie Y, Xia X, Tian J, Zhang K, Tang A. Wnt signaling in cervical cancer?. J Cancer 2018; 9(7):1277-1286. doi:10.7150/jca.22005. Available from https://www.jcancer.org/v09p1277.htm

File import instruction


Cervical cancer (CC) is the second most common malignant cancer in women. CC is difficult to diagnose, has a high recurrence rate, and is resistant to systemic therapies; as a result, CC patients have a relatively poor prognosis. One potential link to CC is the Wnt signaling pathway and its downstream effectors, which regulate cell differentiation, proliferation, migration, and fate. The aberrant activation of Wnt signaling is associated with various cancers, including CC. Recent studies have shown that activating or inhibiting the intracellular signal transduction in this pathway can regulate cancer cell growth and viability. This review will summarize the experimental evidence supporting the significance of the Wnt signaling pathway in CC, and will also discuss the current clinical role of Wnt signaling in CC diagnosis, therapy, and prognosis.

Keywords: Wnt, signaling pathway, CC, β-catenin, HPV